2023 World Conference on Lung Cancer (Posters)-EP11.03. Sarcopenia Is a Poor Predictive Prognostic Factor for Non Small Cell Lung Cancer Patients Who Were Treated with Immune Check Point Inhibitors

EP11.03. Sarcopenia Is a Poor Predictive Prognostic Factor for Non Small Cell Lung Cancer Patients Who Were Treated with Immune Check Point Inhibitors - PDF(Slides)

Back to course

Pdf Summary

Sarcopenia, a condition characterized by muscle loss and chronic inflammation, has been found to negatively affect the immune system. However, its direct impact on the treatment outcomes of immune checkpoint inhibitors (ICI) in non-small cell lung cancer patients has not been well-studied. <br /><br />To analyze this, a study was conducted on 80 lung cancer patients who were treated with ICI as a first-line treatment. The patients were classified into two groups: normal and sarcopenia. The analysis revealed that the sarcopenia group had significantly higher levels of inflammatory cytokines, such as IL-6, IL-8, and IL-10, compared to the normal group. The sarcopenia group also had higher proportions of T regulatory (Treg) cells and exhausted T-cells.<br /><br />Furthermore, the study found that the sarcopenia group had a poor trend in progression-free survival (PFS), although the difference was not statistically significant. This suggests that sarcopenia could be a poor predictive prognostic factor for the treatment of ICI.<br /><br />The study utilized various methods to obtain these results, including a dual energy X-ray absorptiometry test to diagnose sarcopenia, lymphocyte subset analysis, and cytokine profile analysis.<br /><br />In conclusion, sarcopenia is associated with abnormal inflammation and alters the composition of lymphocytes, which can negatively affect the effectiveness of ICI treatment in non-small cell lung cancer patients. These findings highlight the importance of considering sarcopenia as a predictive factor when determining treatment plans for these patients. Further research on the impact of sarcopenia on ICI treatment outcomes is warranted.

Asset Subtitle

Sung Yong Lee

Meta Tag

Speaker Sung Yong Lee

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

Sarcopenia

muscle loss

chronic inflammation

immune system

non-small cell lung cancer

inflammatory cytokines

T regulatory cells

exhausted T-cells

progression-free survival

treatment plans